Dane Leone

Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In
Why This Ayala Pharmaceuticals Analyst Is Bullish
Sell-Side Remains Optimistic On Sage Therapeutics Despite Depression Drug Disappointment
Why This Ayala Pharmaceuticals Analyst Is Bullish
Sell-Side Remains Optimistic On Sage Therapeutics Despite Depression Drug Disappointment
Raymond James Downgrades Ocular Therapeutix, Remains Bullish On Pipeline
Bluebird Bio's Competitive Advantage Is Underappreciated, Raymond James Says In Bullish Initiation

Dane Leone Recent News

3 Reasons To Like Vertex Pharma Shares
Johnson & Johnson Shares Might Break Lower Before They Break Out
This Analyst Is Disappointed With Performance Of Celgene's Mongersen, Ozanimod
After Bluebird's 75% Gain In 2017, Analysts At BTIG Downgrade To Neutral
Here's The Beef With Bluebird's Starbeam Study Results
The Only Bullish Scenario For Juno Therapeutics: Its CEO May Get Fired
Key Reasons BTIG Just Upgraded Kite Pharma
Nesvacumab Key Catalyst For Regeneron In 2017; BTIG Upgrades To Buy
Juno Therapeutics' Hold Is 'More Impactful To Sentiment Than Estimates'
BTIG Is No Longer Selling Juno Therapeutics Stock
Favorable FDA Pathway Should Keep Bluebird's Clinical Studies Flying Straight
Illumina's Poor Streak Is A Sign Of Market Saturation
Sell Juno Therapeutics: BTIG Says It's Trailing The Competition
BTIG Is 'Generally Skeptical' On Kite Pharma Expectations
BTIG Research Upgrades Alere To Buy, Says 10-K Filing Offers 'Fundamental Opportunity'
Celgene Could Achieve 2020 Targets, BTIG Upgrades To Buy
Celgene Downgraded To Netural As Company Might Be Relying Too Heavily On Revlimid
Under-Promising, Over-Delivering: Has Agilent's Management Gained Credibility?
BTIG Comments On Bluebird Bio's Q1 Print, Highlights Future Catalysts
BTIG Downgrades Bruker, Still Likes Long-Term Story
BTIG Starts MacroGenics At Buy, Sees 63% Upside
UPDATE: BTIG Initiates Coverage On Thermo Fisher Scientific Inc.
UPDATE: BTIG Initiates Coverage On Affymetrix, Inc.